RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Lixte Biotechnology Holdings Stock

Lixte Biotechnology Holdings EBIT 2024

Lixte Biotechnology Holdings EBIT

-5.09 M USD

Ticker

LIXT

ISIN

US5393193017

WKN

A3EGAA

In 2024, Lixte Biotechnology Holdings's EBIT was -5.09 M USD, a -19.33% increase from the -6.31 M USD EBIT recorded in the previous year.

The Lixte Biotechnology Holdings EBIT history

YEAREBIT (undefined USD)
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-

Lixte Biotechnology Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Lixte Biotechnology Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Lixte Biotechnology Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Lixte Biotechnology Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Lixte Biotechnology Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Lixte Biotechnology Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Lixte Biotechnology Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Lixte Biotechnology Holdings’s growth potential.

Lixte Biotechnology Holdings Revenue, EBIT and net profit per share

DateLixte Biotechnology Holdings RevenueLixte Biotechnology Holdings EBITLixte Biotechnology Holdings Net Income
20230 undefined-5.09 M undefined-5.09 M undefined
20220 undefined-6.31 M undefined-6.31 M undefined
20210 undefined-6.72 M undefined-6.73 M undefined
20200 undefined-3.27 M undefined-3.26 M undefined
20190 undefined-2.49 M undefined-2.44 M undefined
20180 undefined-2.14 M undefined-2.13 M undefined
20170 undefined-1.81 M undefined-1.81 M undefined
20160 undefined-2.13 M undefined-2.13 M undefined
2015200,000 undefined-2.65 M undefined-2.85 M undefined
20140 undefined-2.4 M undefined-2.77 M undefined
20130 undefined-1.37 M undefined-1.37 M undefined
20120 undefined-2.11 M undefined-3.58 M undefined
20110 undefined-1.87 M undefined-2.07 M undefined
20100 undefined-880,000 undefined-880,000 undefined
20090 undefined-1.55 M undefined-1.55 M undefined
20080 undefined-1.27 M undefined-1.27 M undefined
20070 undefined-1.66 M undefined-1.65 M undefined
20060 undefined-450,000 undefined-560,000 undefined
20050 undefined-30,000 undefined-30,000 undefined

Lixte Biotechnology Holdings stock margins

The Lixte Biotechnology Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lixte Biotechnology Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lixte Biotechnology Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Lixte Biotechnology Holdings's sales revenue. A higher gross margin percentage indicates that the Lixte Biotechnology Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Lixte Biotechnology Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Lixte Biotechnology Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Lixte Biotechnology Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Lixte Biotechnology Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Lixte Biotechnology Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Lixte Biotechnology Holdings Margin History

Lixte Biotechnology Holdings Gross marginLixte Biotechnology Holdings Profit marginLixte Biotechnology Holdings EBIT marginLixte Biotechnology Holdings Profit margin
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %-1,325 %-1,425 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %

Lixte Biotechnology Holdings Aktienanalyse

What does Lixte Biotechnology Holdings do?

Lixte Biotechnology Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Lixte Biotechnology Holdings's EBIT

Lixte Biotechnology Holdings's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Lixte Biotechnology Holdings's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Lixte Biotechnology Holdings's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Lixte Biotechnology Holdings’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Lixte Biotechnology Holdings stock

How much did Lixte Biotechnology Holdings achieve in EBIT for the current year?

In the current year, Lixte Biotechnology Holdings has achieved an EBIT of -5.09 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Lixte Biotechnology Holdings.

How has the EBIT of Lixte Biotechnology Holdings developed in recent years?

The EBIT of Lixte Biotechnology Holdings has increased by -19.331% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Lixte Biotechnology Holdings?

The EBIT of Lixte Biotechnology Holdings is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Lixte Biotechnology Holdings pay?

Over the past 12 months, Lixte Biotechnology Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lixte Biotechnology Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Lixte Biotechnology Holdings?

The current dividend yield of Lixte Biotechnology Holdings is .

When does Lixte Biotechnology Holdings pay dividends?

Lixte Biotechnology Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lixte Biotechnology Holdings?

Lixte Biotechnology Holdings paid dividends every year for the past 0 years.

What is the dividend of Lixte Biotechnology Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lixte Biotechnology Holdings located?

Lixte Biotechnology Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lixte Biotechnology Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lixte Biotechnology Holdings from 11/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.

When did Lixte Biotechnology Holdings pay the last dividend?

The last dividend was paid out on 11/4/2024.

What was the dividend of Lixte Biotechnology Holdings in the year 2023?

In the year 2023, Lixte Biotechnology Holdings distributed 0 USD as dividends.

In which currency does Lixte Biotechnology Holdings pay out the dividend?

The dividends of Lixte Biotechnology Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Lixte Biotechnology Holdings

Our stock analysis for Lixte Biotechnology Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lixte Biotechnology Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.